FIELD: medicine.
SUBSTANCE: treating cardiovascular diseases caused by fibroid heart is ensured by introducing compositions containing vasoactive intestinal peptide (VIP) or its active fragments, in the developed doses and regimen.
EFFECT: involution or prevented development of fibroid heart.
16 cl, 10 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VIP FRAGMENTS AND METHODS FOR USING THEM | 2006 |
|
RU2466738C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF AORTA FIBROSIS | 2010 |
|
RU2536223C2 |
| COMPOSITIONS AND METHODS OF TREATING RENAL DISORDERS | 2009 |
|
RU2519124C2 |
| COMPOSITION FOR TREATMENT OF HYPERTENSION AND/OR FIBROSIS | 2014 |
|
RU2635564C2 |
| THERAPEUTIC AGENT FOR THE TREATMENT OF CARDIOMYOPATHY, PREVIOUS MYOCARDIAL INFARCTION AND CHRONIC HEART FAILURE | 2018 |
|
RU2795320C2 |
| MODIFIED VASOACTIVE INTESTINAL PEPTIDES | 2010 |
|
RU2589255C2 |
| COMPOSITIONS FOR TREATING FIBROSIS AND FIBROSIS-RELATED CONDITIONS | 2016 |
|
RU2712140C2 |
| COMPOSITIONS FOR TREATMENT OF HYPERTENSION AND/OR FIBROSIS | 2017 |
|
RU2752088C1 |
| TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
| TREATING VASCULAR COMPLICATIONS OF DIABETES | 2010 |
|
RU2545718C2 |
